GSK (GSK) Morgan Stanley 24th Annual Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
Morgan Stanley 24th Annual Global Healthcare Conference summary
15 Sep, 2026Oncology strategy and portfolio evolution
Focused on rebuilding capabilities in areas with unmet need, including heme malignancies, gynecological, thoracic, GI, and prostate cancers.
Expanded portfolio through both organic discovery and significant business development, including recent deals with Nuvalent and a tri-specific immune cell engager for multiple myeloma.
Five medicines approved in four years, with a sixth expected by year-end and three more by 2029.
Key assets for 2031 sales targets include B7-H3, B7-H4, velzatinib, neladalkib, and zidesamtinib.
Strategic discipline in selecting areas of focus and avoiding less aligned opportunities.
Business development and deal philosophy
Business development guided by unmet need, differentiation, clinical data strength, and alignment with strategic disease areas.
Nuvalent deal brought two key assets (neladalkib and zidesamtinib) and a discovery pipeline, forming a lung cancer franchise.
Deal sizes vary based on synergy and portfolio fit, with recent transactions ranging from £1–2 billion.
Ongoing openness to both large and small deals, depending on strategic value.
Clinical development highlights
Jideytro (zidesamtinib) showed a 94% objective response rate and strong durability in first-line ROS1-positive lung cancer; regulatory filing planned for Q4.
Neladalkib designed for broad ALK mutation coverage and brain penetration; phase III ALKAZAR trial progressing well with potential for early interim analysis.
Tolerability profile for neladalkib shows manageable, reversible liver transaminitis.
Latest events from GSK
- GBP 1.9bn savings and 22 Phase III starts fuel a >GBP 40bn 2031 sales ambition.GSK
J.P. Morgan UK Leaders Conference - Four- and six-month HIV regimens, pipeline launches and oncology aim to sustain growth through expiries.GSK
Jefferies Global Healthcare Conference - Biomarker-led R&D advances long-acting airway therapies and novel liver programs.GSK
3rd Annual Guggenheim Healthcare Innovation Conference - Specialty-led growth and pipeline investment support reaffirmed FY26 guidance.GSK
Q3 2026 - Oncology data highlighted gains across ADCs, immunotherapy and targeted therapies.GSK
ESMO 2026 Investor Briefing - 14% CER sales growth and upgraded outlooks to >£38bn sales by 2031.GSK
Q4 2023 - Ultra-long-acting biologics, AI-driven R&D, and global partnerships are shaping future growth.GSK
Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum - GBP 1.9bn in savings will fund pipeline growth, with oncology and specialty assets prioritized.GSK
Bank of America Global Healthcare Conference - Accelerated R&D, pipeline reinvestment, and specialty focus drive growth and margin stability.GSK
Bernstein’s 23rd Annual Pan-European Strategic Decisions Conference